Deals Shaping the Medical Industry (10/2011)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
You may also be interested in...
ITM is reaping benefits from long-term investment in radiopharmaceuticals manufacturing and is now looking to challenge its customer, Novartis, by bringing its first product to market.
Evobrutinib flunked its Phase III multiple sclerosis program not because of its known toxicity, but because it didn’t work.
Members of the European Parliament were told that once the list was out, work would begin on identifying the products most vulnerable to supply chain problems.